Superworth

Innoviva profit margin INVA

Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.

Net margin, 12 months
81.2%
Operating margin, 12 months
36.9%
Net margin on a year earlier
+70.8 pts
Peer median
13.3%

Over the twelve months to Jun 30, 2026, Innoviva kept 81.2% of its revenue as net profit, with an operating margin of 36.9% and a gross margin of 72.2%.

Five years earlier its net margin was 72.6%.

The median for 10 large drugmakers of a similar size is 13.3%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY202565.9%39.8%74.8%
FY20246.5%46.5%82.6%
FY202357.9%40.3%86.8%
FY202264.6%n/a95.8%
FY202167.8%95.7%n/a
FY202066.6%95.3%n/a
FY201960.3%94.4%n/a
FY2018n/a91.3%n/a
FY201761.8%84.5%n/a
FY201644.6%81.6%n/a
FY2015−34.8%58.5%n/a
FY2014n/an/an/a
FY2013n/an/an/a
FY2012−13.7%−9.6%n/a
FY2011n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY2681.2%+70.8 pts36.9%
Q1 FY26n/an/a38.1%
Q4 FY2565.9%+59.4 pts39.8%
Q3 FY2532.8%+14.5 pts43.2%
Q2 FY2510.4%−33.6 pts47.7%
Q1 FY25−16.1%−74.4 pts49.3%
Q4 FY246.5%−51.4 pts46.5%
Q3 FY2418.3%+1.1 pts50.3%
Q2 FY2444.0%−36.3 pts45.2%
Q1 FY2458.2%−15.1 pts39.5%
Q4 FY2357.9%−6.7 pts40.3%
Q3 FY2317.2%−61.2 pts43.9%

Against its peers

Companies in Drug Manufacturers - General nearest Innoviva's size, closest first, today.

CompanyProfit margin
INVAInnoviva81.2%
ANABAnaptysbion/m
PCRXPacira BioSciences2.0%
PAHCPhibro Animal Health6.6%
ANIPANI Pharmaceuticals11.1%
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals10.8%
HRMYHarmony Biosciences18.9%
PBHPrestige Consumer Healthcare15.6%
ABUSArbutus Biopharma84.2%
NRIXNurix Therapeutics42.0%
Peer median13.3%

Where Innoviva ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Innoviva

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.